Research programme: trastuzumab biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Research programme: trastuzumab biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: Anti-HER2/neu mAb biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; Fderceptin; Herceptin biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Latest Information Update: 06 May 2015

Price : $50

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 06 May 2015 Preclinical trials in Breast cancer in China (Parenteral), before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top